Literature DB >> 1991821

Interleukin-6 is elevated in plasma in multiple sclerosis.

K Frei1, S Fredrikson, A Fontana, H Link.   

Abstract

Levels of interleukin-6 (IL-6)--a cytokine which induces immunoglobulin production of activated B cells--were measured in cerebrospinal fluid (CSF) and plasma of patients with multiple sclerosis (MS), acute meningo-encephalitis (AM) and muscular tension headache (TH). MS patients had in repeated samples higher levels of IL-6 in plasma compared to patients with AM and TH. IL-6 concentrations in MS plasma were about 17 times higher than MS CSF, while in AM 20-fold higher levels were found in CSF compared to plasma during the acute stage. IL-6 in AM CSF decreased rapidly during clinical recovery. No correlation was found between IL-6 in MS patients' plasma or CSF and disease activity. The functional significance of elevated IL-6 concentrations in MS plasma is unknown, although the findings support the hypothesis of a systemic B cell response in MS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991821     DOI: 10.1016/0165-5728(91)90020-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

1.  Inflammatory cytokines determine the susceptibility of human CD8 T cells to Fas-mediated activation-induced cell death through modulation of FasL and c-FLIP(S) expression.

Authors:  Anna von Rossum; Randall Krall; Nichole K Escalante; Jonathan C Choy
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons.

Authors:  D I Orellana; R A Quintanilla; C Gonzalez-Billault; R B Maccioni
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

3.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

4.  Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation.

Authors:  Ana Paula Kallaur; Josiane Lopes; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche; Elaine Regina Delicato de Almeida; Helena Kaminami Morimoto; Wildea Lice Carvalho Jennings de Pereira; Daniele Frizon Alfieri; Sueli Donizete Borelli; Domacio Ramon Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-09-24       Impact factor: 5.590

Review 5.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  Cellular basis of T-cell autoreactivity in autoimmune diseases.

Authors:  C Carnaud; J F Bach
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

7.  Neuroprotection of interleukin-6 against NMDA-induced neurotoxicity is mediated by JAK/STAT3, MAPK/ERK, and PI3K/AKT signaling pathways.

Authors:  Xiao-Xia Fang; Xiao-Lin Jiang; Xin-Hua Han; Yu-Ping Peng; Yi-Hua Qiu
Journal:  Cell Mol Neurobiol       Date:  2012-11-16       Impact factor: 5.046

8.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

Review 9.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

Review 10.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.